Edgewise Therapeutics, Inc. (EWTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Edgewise Therapeutics, Inc. (EWTX) Healthcare & Pipeline Overview

Edgewise Therapeutics, Inc. is a biopharmaceutical firm specializing in small molecule therapies for musculoskeletal disorders, with a primary focus on dystrophinopathies. Their lead candidate, EDG-5506, has completed Phase 1 trials, positioning the company in the competitive biotechnology landscape targeting genetically defined muscle disorders.

What Is the Investment Thesis for EWTX?

Edgewise Therapeutics presents a notable research candidate within the biotechnology sector, driven by its focus on developing small molecule therapies for musculoskeletal diseases. The company's lead product candidate, EDG-5506, targeting dystrophinopathies, has completed Phase 1 clinical trials, demonstrating initial safety. A key value driver is the potential for EDG-5506 to address the root cause of Duchenne and Becker muscular dystrophy, representing a significant unmet medical need. Growth catalysts include the advancement of EDG-5506 through further clinical trials (Phase 2 and 3) and the expansion of the company's pipeline with additional precision medicine product candidates. The company's market capitalization of $4.62B reflects investor confidence in its technology and development programs. Potential risks include clinical trial failures, regulatory hurdles, and competition from other companies developing therapies for musculoskeletal diseases. Successful clinical development and commercialization of EDG-5506 could drive significant revenue growth and shareholder value.

Based on FMP financials and quantitative analysis

EWTX Key Highlights

Lead product candidate EDG-5506 has completed Phase 1 clinical trials, demonstrating initial safety and tolerability.

• Focus on small molecule therapies offers potential advantages in terms of oral bioavailability and manufacturing scalability.
• Targets genetically defined muscle disorders, addressing significant unmet medical needs.
• Market capitalization of $4.62B reflects investor confidence in the company's technology and development programs.
• Developing a pipeline of precision medicine product candidates that target key muscle proteins and modulators.

Who Are EWTX's Competitors?

EWTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are EWTX's Key Strengths?

Focus on small molecule therapies offers potential advantages.

• Lead product candidate has completed Phase 1 clinical trials.
• Targets genetically defined muscle disorders with unmet needs.
• Experienced management team with expertise in drug development.

What Are EWTX's Weaknesses?

Limited number of product candidates in the pipeline.

• Reliance on the success of EDG-5506.
• High cash burn rate associated with drug development.
• Subject to regulatory risks and clinical trial uncertainties.

What Could Drive EWTX Stock Higher?

Initiation of Phase 2 clinical trials for EDG-5506 in Duchenne muscular dystrophy.

• Announcement of preclinical data for new pipeline programs.
• Continued enrollment of patients in clinical trials.
• Expansion of partnerships with patient advocacy groups.

What Are the Key Risks for EWTX?

Negative return on equity (-32.5%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for EDG-5506 or other pipeline programs.
• Regulatory delays or rejection of marketing applications.
• Competition from other companies developing therapies for musculoskeletal diseases.
• Intellectual property challenges.
• Difficulty in raising additional capital to fund drug development.

What Are the Growth Opportunities for EWTX?

• Expansion of EDG-5506 into additional indications: Beyond Duchenne and Becker muscular dystrophy, EDG-5506 may have potential in other dystrophinopathies or related muscle disorders. Exploring these additional indications could significantly expand the market opportunity for EDG-5506. The timeline for this expansion would depend on preclinical and clinical studies to evaluate the drug's efficacy and safety in these new indications. The market size for related muscle disorders could add several billion dollars to the potential revenue stream.
• Advancement of pipeline programs: Edgewise is developing a pipeline of precision medicine product candidates that target key muscle proteins and modulators. Advancing these programs through preclinical and clinical development could lead to the discovery and commercialization of additional therapies for musculoskeletal diseases. The timeline for these programs will vary depending on the specific target and the stage of development. Successful pipeline expansion could establish Edgewise as a leader in the treatment of genetically defined muscle disorders.
• Strategic partnerships and collaborations: Partnering with larger pharmaceutical companies or other biotechnology firms could provide Edgewise with access to additional resources, expertise, and funding to accelerate the development and commercialization of its product candidates. These partnerships could take the form of licensing agreements, co-development agreements, or joint ventures. The timing and structure of these partnerships will depend on the specific opportunities that arise. Strategic collaborations could significantly enhance Edgewise's ability to bring its therapies to market.
• Geographic expansion: Initially focused on the US market, Edgewise could expand its commercial reach to other countries, including Europe and Asia. This geographic expansion would require establishing regulatory approvals, marketing infrastructure, and distribution networks in these new markets. The timeline for geographic expansion would depend on the regulatory landscape and market dynamics in each country. Expanding into new geographic markets could significantly increase the company's revenue potential.
• Development of novel drug delivery systems: Exploring novel drug delivery systems could improve the bioavailability, efficacy, and patient compliance of Edgewise's therapies. This could involve developing sustained-release formulations, targeted delivery systems, or other innovative approaches. The timeline for developing these new delivery systems will depend on the specific technology and the stage of development. Improved drug delivery could enhance the therapeutic benefits of Edgewise's products and provide a competitive advantage.

What Are EWTX's Competitive Advantages?

• Proprietary small molecule therapies targeting specific muscle proteins.
• Strong intellectual property protection through patents.
• Expertise in developing therapies for genetically defined muscle disorders.
• Established relationships with key opinion leaders and patient advocacy groups.

What Does EWTX Do?

Edgewise Therapeutics, Inc., founded in 2017 and headquartered in Boulder, Colorado, is a biopharmaceutical company dedicated to developing innovative small molecule therapies for musculoskeletal diseases. The company's mission is to address the underlying causes of genetically defined muscle disorders, offering potential treatments where limited options currently exist. Their lead product candidate, EDG-5506, is an orally administered small molecule designed to target the root cause of dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). EDG-5506 has successfully completed Phase 1 clinical trials, demonstrating initial safety and tolerability. Edgewise is developing a pipeline of precision medicine product candidates that target key muscle proteins and modulators. This approach allows them to address a range of genetically defined muscle disorders beyond DMD and BMD. The company's focus on small molecule therapies offers potential advantages in terms of oral bioavailability, manufacturing scalability, and cost-effectiveness compared to other therapeutic modalities. Edgewise is committed to advancing its pipeline through rigorous preclinical and clinical development, with the goal of bringing meaningful new therapies to patients with musculoskeletal diseases. The company's strategy involves identifying novel targets, developing potent and selective small molecule inhibitors or activators, and conducting well-designed clinical trials to demonstrate efficacy and safety. As of 2026, Edgewise continues to focus on expanding its research and development efforts to address unmet needs in the treatment of muscle disorders.

What Products and Services Does EWTX Offer?

• Develops small molecule therapies for musculoskeletal diseases.
• Focuses on treating genetically defined muscle disorders.
• Lead product candidate, EDG-5506, targets dystrophinopathies.
• Conducts preclinical and clinical studies to evaluate the safety and efficacy of its therapies.
• Seeks to address the root causes of muscle disorders.
• Aims to provide orally bioavailable therapies for patients.
• Develops precision medicine product candidates that target key muscle proteins and modulators.

How Does EWTX Make Money?

• Develops and patents novel small molecule therapies.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA.
• Commercializes approved therapies through sales and marketing efforts.

What Industry Does EWTX Operate In?

Edgewise Therapeutics operates within the biotechnology industry, which is characterized by high levels of innovation, risk, and potential reward. The market for therapies targeting musculoskeletal diseases is substantial, driven by the prevalence of conditions such as Duchenne muscular dystrophy and Becker muscular dystrophy. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms developing various therapeutic modalities, including gene therapies, cell therapies, and small molecules. Edgewise's focus on small molecule therapies provides a differentiated approach, offering potential advantages in terms of cost-effectiveness and ease of administration. The biotechnology industry is subject to stringent regulatory requirements and faces challenges related to clinical trial success, intellectual property protection, and market access.

Who Are EWTX's Key Customers?

• Patients with musculoskeletal diseases, particularly dystrophinopathies.
• Physicians who treat patients with these conditions.
• Hospitals and clinics that provide care for these patients.
• Payers, including insurance companies and government healthcare programs.

Over the past six months, Edgewise Therapeutics, Inc. insiders filed 30 SEC Form 4 transactions — 12 sales and 18 purchases. On net that is roughly 701K shares acquired (about $14.3M) — insiders putting money in tends to read as conviction.

Wall Street analysts project Edgewise Therapeutics, Inc. revenue of about $2.3M for fiscal 2026, with EPS near $-2.05. The estimate reflects 8 contributing analysts.

Edgewise Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 0.8% above estimates on average.

Edgewise Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 86.46 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Edgewise Therapeutics, Inc. stands at -32.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 22.61 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.9%, the inverse of the P/E and a quick read on earnings relative to price.

Edgewise Therapeutics, Inc. (EWTX) Valuation Context

Valued at $4.62B, EWTX is classified as a mid-cap stock. Analyst price targets span from $36.00 to $66.00, with a consensus of $51.90. At the current price of $42.90, that implies approximately 21% upside potential. Relative to its peer group, EWTX's quantitative score of 66/100 is below the peer average of 81/100.

Company Profile

Edgewise Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boulder, US. The company is led by CEO Kevin Koch. EWTX has traded publicly since 2021.

EWTX Financials

EWTX Latest News

EWTX Analyst Consensus

EWTX MoonshotScore

Common Questions About EWTX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources